Cancer Rop Co. Ltd. - Asset Resilience Ratio
Cancer Rop Co. Ltd. (180400) has an Asset Resilience Ratio of 1.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Cancer Rop Co. Ltd.'s Asset Resilience Ratio has changed over time. Check Cancer Rop Co. Ltd. PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cancer Rop Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 180400 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.58 Billion | 1.37% |
| Total Liquid Assets | ₩1.58 Billion | 1.37% |
Asset Resilience Insights
- Limited Liquidity: Cancer Rop Co. Ltd. maintains only 1.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cancer Rop Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Cancer Rop Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
Annual Asset Resilience Ratio for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Cancer Rop Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.02% | ₩1.58 Billion ≈ $1.07 Million |
₩154.87 Billion ≈ $104.96 Million |
-1.19pp |
| 2024-12-31 | 2.21% | ₩1.60 Billion ≈ $1.08 Million |
₩72.36 Billion ≈ $49.04 Million |
-2.84pp |
| 2023-12-31 | 5.05% | ₩5.04 Billion ≈ $3.42 Million |
₩99.94 Billion ≈ $67.73 Million |
+3.23pp |
| 2022-12-31 | 1.81% | ₩1.56 Billion ≈ $1.06 Million |
₩85.95 Billion ≈ $58.25 Million |
+0.40pp |
| 2018-12-31 | 1.41% | ₩950.92 Million ≈ $644.42K |
₩67.54 Billion ≈ $45.77 Million |
-32.27pp |
| 2016-12-31 | 33.67% | ₩10.00 Billion ≈ $6.78 Million |
₩29.70 Billion ≈ $20.13 Million |
-11.88pp |
| 2015-12-31 | 45.55% | ₩10.10 Billion ≈ $6.84 Million |
₩22.17 Billion ≈ $15.03 Million |
+44.25pp |
| 2014-12-31 | 1.30% | ₩100.00 Million ≈ $67.77K |
₩7.70 Billion ≈ $5.22 Million |
-- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more